Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...

Gilead and the Gilead logo, Truvada, and Truvada for PrEP are registered trademarks ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest ...

That brand is more than just a logo - it’s ... as B2C firms do. Some pharmaceutical brands are even experimenting with influencers, including a recent campaign from Gilead Science.

Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is ...